Drug Discovery

The regulatory landscape for pharmaceutical development has reached a definitive turning point as the U.S. Food and Drug Administration officially moves away from the decades-old requirement of two pivotal clinical trials in favor of a streamlined, single-trial default for new drug approvals. This

The persistent challenge of treating metastatic castration-resistant prostate cancer has long centered on the tumor’s ability to remain invisible to the body’s natural immune defenses while resisting standard therapeutic interventions. A groundbreaking preclinical study led by researchers at Weill

The persistent fragility of the American pharmaceutical supply chain has reached a critical juncture where relying solely on reactive measures is no longer a viable strategy for national health security. To address this, the Food and Drug Administration has introduced the PreCheck Pilot Program, a

The global medical landscape continues to face a critical shortage of donor organs, leaving millions of patients dependent on invasive treatments like dialysis while they wait for life-saving transplants that may never arrive. For a long time, the promise of growing functional human organs in a

The global pharmaceutical landscape is undergoing a radical transformation as traditional chemical synthesis gives way to the intricate, living architecture of biological medicine. At the heart of this shift lies the upstream bioprocessing equipment sector, which is increasingly recognized as the

The cardiovascular research community stood in stunned silence this week as a once-heralded clinical champion stumbled at the very finish line of its long journey toward regulatory approval. Shares of Ionis Pharmaceuticals plummeted by 21% in early trading, while AstraZeneca faced an 8% drop,